TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Duration of non-Invasive ventilation (NIV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prenatal Distress Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pregnancy-Related Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Requirement of External Laryngeal Manipulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Blood Coagulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of dysphagia improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coinfection diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Priorities and required outcomes of younger patients undergoing THR
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in slope of eGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Recurrent hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Mean monopolar 1 plus 2 (MP1+2) impedances (kOhms) at 3 months postactivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in word recognition score in the preferred unilateral listening mode in quiet from preimplantation to 3 months postactivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with one or more adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with one or more serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with one or more adverse event of special interest
Endpoint domain: Adverse events/effects
Primary endpoint: Quantity of bone (vertical bone height)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Participants Achieving PASI 100
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving At Least 10% Weight Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in 24-h cough frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Community Participation Measure
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Area under the plasma concentration-time curve (AUC) of olezarsen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum plasma concentration of olezarsen (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in shoulder function and pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in MADRS Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: EEG power in spectral frequency bands
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Phase Locking Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in best-corrected visual acuity (letter score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in inflammation levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Degree of agreement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Movement Imagination Questionnaire-3
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mental Chronometry Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants with Treatment -Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in population of Lactobacillus plantarum and Bifidobacterium bifidum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maximal muscle force
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: AF freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration versus time curve (AUC0-inf) of bomedemstat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functionality of the eustachian tube
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attendance at summary consultation with general practitioner
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Urinary incontinence awareness and attitude
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain Medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Vestibular activity participation scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Serum concentration of metals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary concentration of metals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with altered values of respiratory system impedance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Serum concentration of zonulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum concentration of protein oxidation products
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ObsQor-10 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Acrophobia-related interpretational processing biases
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: 2 year CNS relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Emotion Recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Theory of mind - NEPSY-II
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Theory of mind - Happé's Strange Stories
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Theory of mind - RMETC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Cmax) of ABBV-552
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Cmax (peak time, Tmax) of ABBV-552
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of TEAEs with Grade ≥3
Endpoint domain: Adverse events/effects
Primary endpoint: Stabilometric Balance Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical breast exam (CBE) utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cognitive load level
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Achievement of vIGA-AD score of 0 or 1 with ≥2 point reduction from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of ≥75% reduction in EASI score from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate (ORR) with carfilzomib and dexamethasone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Response Rate (ORR) with pomalidomide and dexamethasone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in CSF MTBR-tau-243
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in cellular response of autoreactive immune cells to antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of diaper dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Symptom score of overactive bladder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving >50% reduction in Total Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta QTc Fridericia (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of licaminlimab in dry eye disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in myofibre cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in muscle fibre cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of spinal cord ischemia improvement or resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiometabolic Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of days of abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Lesion FAPI uptake on PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Total FAPI-positive tumor volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: UNC DEMS Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reliability of ocular motor detection system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom intensity of premenstrual syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interference of premenstrual syndrome
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Relative change in glucose disposal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Surgical Fear Scale (SFS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Surgical Site Infection Occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Allergic Reaction and Skin Irritation
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Clinical Laboratory Abnormalities Meeting Pre-Defined Categorical Criteria Without Regard to Baseline Abnormality
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Vital Signs Abnormalities Meeting Pre-Defined Categorical Criteria
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Abnormal Electrocardiogram (ECG) Meeting Pre-Defined Categorical Criteria
Endpoint domain: Adverse events/effects
Primary endpoint: Musculoskeletal System Perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: donor microbial engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of congenital HCMV infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Study Retention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction With Intervention
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in in-vivo dental biofilm accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COPD Assessment Test (CAT) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants who adhere to ≥ 80% of prescribed actuations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Positive and Negative Symptoms Scale (PANSS Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electroencephalogram analysis to assess brain electrical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in smooth pursuit eye tracking from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cumulative diagnostic yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saint George Quality of life questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of attempted venipunctures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rickets severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Non-Alcoholic Fatty Pancreas Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prevalence of IPE in MAFLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Treatment efficacy for chlamydia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Feeling concerned by difficulties with sexual arousal
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Arousal-Sensation Domain score change
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Modified Rankin Scale (mRS) scores of 0-1 at Day 90
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foundational mathematic and literacy skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Prosocial
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Social and emotional problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composite of all-cause mortality, stroke, spontaneous myocardial infarction, urgent repeat revascularization or heart failure readmission
Endpoint domain: Mortality/survival
Primary endpoint: Dose coverage of target volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial hyperemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Objective Response Rate (ORR) Per mRECIST
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Average difference in change of functional quality of life (QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Progression-free survival - local control
Endpoint domain: Mortality/survival
Primary endpoint: Quantification of fluorescent signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in clinician rate of antibiotic prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in number of antibiotic rounds per patient
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in costs associated with management of pediatric patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Beck Depression Inventory (BDI) Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Beck Anxiety Inventory (BAI) Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: time to seizure onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants Reporting Adverse Reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Reporting Serious Adverse Reactions (SADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity and specificity of Kintsugi's technology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intention to change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment-seeking behavior
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Brain functional MRI biomarker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of subjects with emergence delirium
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Tumor-infiltrating Lymphocyte (TIL) Cells in Surgically Resected Tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC [0-∞])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve During One Dosing Interval (AUCτ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of recurrence at endoscopic resection scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of the iStatis Syphilis Ab Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-Reported Social Cognition
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Changes in upper limb function Disabilities of the Arm, Shoulder and Hand (DASH) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain intensity (Visual Analog Scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical jump test for lower extremity strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-Hop test for lower extremity power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Star excursion balance test for dynamic balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Facial Wrinkles and Fine Lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary vasomotor function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional recovery according to UW-mRS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average postoperative pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total postoperative opioid use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Complete hematological response rate (CHR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Strengths and Difficulties Questionnaire (ADHD subscale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of cardiovascular events indicative of progression of pre-existing cardiovascular conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of new cardiovascular diseases events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MDS-UPDRS Part III OFF Medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Prevalence of HS1,2 enhancer alleles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Total Duloxetine: area under the plasma concentration-time curve from 0 to 72 hours (AUC0-72)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Duloxetine: Maximum plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Duloxetine: Time to achieve maximum plasma concentration (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tc99m-MAA uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Edmonton Symptom Assessment Scale (ESAS) Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Missoula-VITAS Quality of Life Index (MVQOLI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Weekly Moderate-to-Vigorous Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Participants Adhering to PA Guidelines
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Step Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 2013 Atherosclerotic Cardiovascular Disease (ASCVD) Risk Calculator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Surgical pressure injury development
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the most problematic behavior Numerical Rating Score (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of seizure-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in caregiver impression of overall severity of symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in Hs-Troponin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Post-COVID Functional Status Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Rate of included patients
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of patients remaining in the study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Advance care planning rate achieved
Endpoint domain: Resource use
Endpoint subdomain: Other resource use